Pain News and Research

Latest Pain News and Research

Study shows relationship between nasal symptoms and severe asthma

People with multi-symptom asthma more often have night-time awakenings due to asthma-symptoms, a sign of severe asthma. Researchers writing in BioMed Central's open access journal Respiratory Research have shown that asthma with multiple symptoms is more highly prevalent than previously suggested, comprising 20- 25% of all asthmatics.

26 Nov 2010

$ESCEO and IOF publish position paper on link between upper thigh bone fractures and bisphosphonate use$

ESCEO and IOF publish position paper on link between upper thigh bone fractures and bisphosphonate use

Leading experts from the European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF) have published a timely position paper on the association between subtrochanteric femoral (upper thigh bone) fractures and long-term treatment with bisphosphonates.

25 Nov 2010

American Board Diplomat joins Ascendant Neuro for treating pain management

Ascendant Neuro is pleased to announce the addition of Jack A. Chapman, M.D., a nationally recognized pain management specialist, who will work to further advance the group's minimally invasive pain treatment techniques through the innovative use of neurostimulators and other conservative treatments.

25 Nov 2010

Cannabis compounds trigger immune cells that promote cancer growth

An international team of immunologists studying the effects of cannabis have discovered how smoking marijuana can trigger a suppression of the body's immune functions. The research, published in the European Journal of Immunology, reveals why cannabis users are more susceptible to certain types of cancers and infections.

25 Nov 2010

End-of-life care raises difficult questions about quality issues

PBS Frontline has kicked off a series called Facing Death, which explores the way Americans die, issues around extending life or prolonging death, uncertainty, talking about the end of life and modern medicine's trade offs.

24 Nov 2010

USFDA grants Sun Pharma tentative marketing approval for generic Cymbalta

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules.

24 Nov 2010

Ziconotide could promote suicidal tendencies in vulnerable patients: Research

24 Nov 2010

DePuy Orthopaedics issues recall on ASR XL Acetabular System and Hip Resurfacing System

DePuy Orthopaedics, Inc., a division of Johnson & Johnson issued a recall on its ASR XL Acetabular System (a hip socket used in traditional hip replacement surgery) and ASR Hip Resurfacing System (a partial hip replacement that involves placing a metal cap on the ball of the femur) -- both of which have been used in hip replacement surgery.

24 Nov 2010

Today's Op-Eds: HMOs, the 'fixed' middlemen; you can't keep your coverage; the (in) effectiveness of medical cost control

Wouldn't it be better to let HMOs compete to offer the cheapest most innovative plans-rather than having the plans defined by new exchanges that must follow federal rules and meanwhile allow the HMOs a generous fixed middleman share of total health pie.

23 Nov 2010

African American cigarette smokers at higher risk of rheumatoid arthritis

A new study determined that African Americans who smoke cigarettes have a higher risk of developing rheumatoid arthritis (RA). RA risk is more pronounced among individuals positive for the HLA-DRB1 shared epitope, a genetic risk factor for RA. Findings from this study—the largest to date examining the impact of smoking on RA risk in an African American population—are available in the December issue of Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR).

23 Nov 2010

Ziconotide could promote suicidal tendencies: Study

The active agent ziconotide, the synthetic toxin of the cone snail (Conus magus), was acclaimed a safe alternative to morphine when it was introduced six years ago. Now it is increasingly suspected of causing patients to commit suicide. Researchers working under the auspices of Prof. Christoph Maier (Director of the Pain Clinic Bergmannsheil at the Ruhr University in Bochum) presume that ziconotide not only suppresses the transmission of pain stimuli, but also deteriorates the frame of mind and could simultaneously reduce anxiety and impulse control.

23 Nov 2010

Rates of hospital emergency department use greater among women and low-income, older and rural Americans

Americans age 18 and older made over 98 million trips to hospital emergency departments in 2008 for problems ranging from broken bones to heart attacks, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. This represents 78 percent of the overall nearly 125 million visits that year.

23 Nov 2010

Arthritis Foundation, Covidien join forces to help Americans suffering from osteoarthritis

The Arthritis Foundation and Covidien have joined forces to help advance awareness and support for millions of people suffering from osteoarthritis in the United States.

23 Nov 2010

Winston announces Phase II study results of Dolorac for chronic migraine at Lazard Conference

Winston Pharmaceuticals, Inc. a specialty pharmaceutical company focused on developing and commercializing novel pain management therapies, announced the results of its Phase II study on its patented Dolorac Nasal Solution (doxepin 0.4%) for prophylaxis of chronic migraine at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.

22 Nov 2010

UC San Diego designated as Blue Distinction Center

UC San Diego Health System has been designated as a Blue Distinction Center for Spine Surgery and a Blue Distinction Center for Knee and Hip Replacement. This honor is awarded to medical facilities that have demonstrated expertise in delivering quality health care in certain specialty medical areas by the Blue Cross and Blue Shield Association.

22 Nov 2010

FDA grants Impax tentative approval for generic Cymbalta NDA

Impax Laboratories, Inc. confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company's Abbreviated New Drug Application for generic version of Cymbalta® delayed-release (duloxetine hydrochloride) 20, 30 and 60 mg capsules.

22 Nov 2010

Neurocrine announces results from elagolix Phase II Daisy PETAL study in endometriosis

Neurocrine Biosciences, Inc. today announced results from the open-label portion of the six month Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

22 Nov 2010

Convergence enters drug discovery collaboration with Selcia for chronic pain treatment

Convergence Pharmaceuticals Limited, the new company focused on the development of novel and high value analgesic medicines, and Selcia Limited, a contract research organisation, today are pleased to announce that they have entered into a drug discovery collaboration to identify and develop high quality candidate molecules for the treatment of chronic pain.

22 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.

22 Nov 2010

Pain News and Research

Latest Pain News and Research

Study shows relationship between nasal symptoms and severe asthma

ESCEO and IOF publish position paper on link between upper thigh bone fractures and bisphosphonate use

American Board Diplomat joins Ascendant Neuro for treating pain management

Cannabis compounds trigger immune cells that promote cancer growth

End-of-life care raises difficult questions about quality issues

USFDA grants Sun Pharma tentative marketing approval for generic Cymbalta

Ziconotide could promote suicidal tendencies in vulnerable patients: Research

DePuy Orthopaedics issues recall on ASR XL Acetabular System and Hip Resurfacing System

Today's Op-Eds: HMOs, the 'fixed' middlemen; you can't keep your coverage; the (in) effectiveness of medical cost control

African American cigarette smokers at higher risk of rheumatoid arthritis

Ziconotide could promote suicidal tendencies: Study

Rates of hospital emergency department use greater among women and low-income, older and rural Americans

Arthritis Foundation, Covidien join forces to help Americans suffering from osteoarthritis

Winston announces Phase II study results of Dolorac for chronic migraine at Lazard Conference

UC San Diego designated as Blue Distinction Center

FDA grants Impax tentative approval for generic Cymbalta NDA

Neurocrine announces results from elagolix Phase II Daisy PETAL study in endometriosis

Convergence enters drug discovery collaboration with Selcia for chronic pain treatment

VYTORIN reduces major vascular events in patients with chronic kidney disease

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Pain News and Research

Latest Pain News and Research

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in